TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [08/17/2018 12:17 PDT] TearLab Corporation (NASDAQ:TEAR), Up By 100.00% ($0.18) From $0.184 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/17/2018 08:10 PDT] TEAR Expected to Trade Down After Bearish Patterns Develop
• [08/14/2018 07:04 PDT] TEAR Expected to Trade Up After Bullish Patterns Develop
• [07/06/2018 11:23 PDT] TearLab Corporation (NASDAQ:TEAR), Down By 15.24% ($0.03) From $0.210 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [06/27/2018 06:21 PDT] TEAR Expected to Trade Down After Bearish Patterns Develop